For four years the top of the semaglutide ladder was 2.4 mg. Wegovy HD moves it to 7.2 mg, three times the dose in a new pen, and the reason it exists is the number tirzepatide put on the board: Novo needed a semaglutide that could get closer to 20%. The trial says it does. The price says it costs $50 a month more to find out.
What it is
Wegovy HD is the same semaglutide as every other Wegovy pen, at a 7.2 mg weekly dose. It is not a new molecule and not a new mechanism. Novo lists it on its pharmacy page as "Wegovy HD (semaglutide) injection 7.2 mg" as a distinct product from the standard pens, which run from 0.25 to 2.4 mg.3 The ladder up to 2.4 mg is unchanged; HD is a further step above it for people who have reached the top of the standard climb.
What the trial found
STEP UP was a 72-week trial in 1,407 adults with a BMI of 30 or more and no diabetes, across 11 countries, randomised five to one to one between 7.2 mg, 2.4 mg and placebo.1 The design matters: the 2.4 mg arm makes this a direct comparison of the new dose against the old one, in the same people, under the same conditions.
| At week 72 | 7.2 mg | 2.4 mg | Placebo |
|---|---|---|---|
| Body weight | −18.7% | −15.6% | −3.9% |
| Difference vs 2.4 mg | −3.1 points (95% CI −4.7 to −1.6) | ||
| Participants | 1,005 | 201 | 201 |
Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.
STEP UP, interpretation
The other comparison people will make is with tirzepatide, and it is worth being careful. Tirzepatide's 20.2% comes from a different trial, SURMOUNT-5, where it was run against semaglutide 2.4 mg and won by 6.5 points.4 Wegovy HD has not been run against tirzepatide. Putting the two trials side by side, 18.7% against 20.2%, suggests the gap has narrowed to about a point and a half. But that is two trials with two populations. The honest statement is that HD closes most of the distance, without a head-to-head to say exactly how much.
Side effects at the higher dose
The obvious worry is that three times the dose means three times the nausea, and the trial's own summary does not read that way. Serious adverse events, the category that includes anything requiring hospital care, were reported by 6.8% on 7.2 mg, 10.9% on 2.4 mg, and 5.5% on placebo.2 The 2.4 mg arm was small (201 people), so its higher figure should not be over-read. What the trial does show is that the higher dose did not produce a higher rate of serious events than the standard one.
The ordinary gut effects, nausea, diarrhoea, constipation and vomiting, are dose-related on every GLP-1 and there is no reason to expect 7.2 mg to be exempt. The trial's authors describe the profile as favourable. The label percentages for the standard dose are in the side-effect guide. The practical rule from every label, climb slowly and hold a step if you are struggling, applies with more force at the top of the ladder than anywhere else.
What it costs
Novo sells it direct to cash patients at $399 a month, against $349 for every standard-dose Wegovy pen.3 So the premium for the higher dose is $50, or about 14%, for a further 3.1 points of body weight.
| Per month, direct from Novo | Price |
|---|---|
| Wegovy pen, 0.25 to 2.4 mg | $349 |
| Wegovy HD pen, 7.2 mg | $399 |
| Wegovy tablet, 1.5 to 25 mg | $149 to $299 |
| Zepbound, 10 to 15 mg (the tirzepatide trial doses) | $699 |
Set against the tirzepatide comparison, that is the interesting number. The 18.7% dose of semaglutide is $399. The 20.2% dose of tirzepatide is $699. If the two trials' results are taken at face value, the last point and a half costs $300 a month.
Through insurance, the HD pen is a Wegovy product and covered where Wegovy is covered, subject to the plan's own rules on dose. Novo's savings card applies to commercially insured patients with coverage, as it does to the standard pens. Whether your plan covers Wegovy at all is in the coverage sheets.
Who it is for
The trial enrolled people starting fresh, but the product's obvious use is the person who has climbed to 2.4 mg, plateaued, and would otherwise be looking at switching to tirzepatide. HD offers a further step on the same molecule, at $50 more rather than $350 more, without starting a new drug's ladder from the bottom. The alternative for that same person is set out in switching between Wegovy and Zepbound; the choice is now between a higher dose of the drug you know and a stronger drug you do not.
The honest summary
Wegovy 7.2 mg is standard Wegovy with a higher ceiling: three more points of body weight in its trial, no increase in serious adverse events, $50 a month more. It makes semaglutide competitive with tirzepatide for the first time, at roughly half the cash price of tirzepatide's top doses, and it has not yet been tested against tirzepatide directly. For someone at the top of the standard ladder, it is a new option that did not exist a year ago.